News & Updates

Vancouver, BC, March 25, 2025 – SOLVE FSHD, a venture philanthropic organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), is pleased to announce a strategic collaboration with Transcripta Bio, a cutting-edge AI-driven drug discovery company. This collaboration will focus on leveraging Transcripta Bio’s advanced drug screening platform to identify and develop promising therapeutic candidates …

Vancouver, BC, December 5, 2024 – SOLVE FSHD, a venture philanthropy organization dedicated to catalyzing innovation and overcoming barriers to accelerate new therapies for facioscapulohumeral muscular dystrophy (FSHD), is calling on innovators worldwide to compete for the USD$10 million FSHD Bonus Prize, part of the XPRIZE Healthspan Competition launched on November 29, 2023. As part of …

SOLVE FSHD AnnouncesNew Collaborative Research Grants to Accelerate Novel Potential Therapeutics for Facioscapulohumeral Muscular Dystrophy (FSHD) VANCOUVER, B.C., July 11, 2023 – SOLVE FSHD, a venture philanthropy organization catalyzing innovation and removing barriers to accelerate new therapies for FSHD, announced today that it has awarded grants totalling USD $1.4M to four new collaborative research projects that address critical …

SOLVE FSHD invests in Epic Bio for the development of a novel treatment for Facioscapulohumeral Muscular Dystrophy Investment will further accelerate the development of EPI-321 VANCOUVER, B.C., April 18, 2023 – SOLVE FSHD, a venture-philanthropic organization catalyzing the pace of innovation to accelerate a cure for FSHD, announced today an investment in Epic Bio, a biotechnology …

Vita Therapeutics Closes $31 Million Series B Financing to Develop Cell Therapies for Neuromuscular Diseases and Cancers – Fundraising led by Cambrian BioPharma and Solve FSHD –– Company expands pipeline with new program, VTA-120, for the treatment of facioscapulohumeral muscular dystrophy (FSHD) – Baltimore, MD, October 12, 2022 – Vita Therapeutics, a cell engineering company harnessing …

SOLVE FSHD Invests US $1 Million in miRecule to Accelerate Development of Best-in-Class Antibody-RNA Conjugate to Treat Facioscapulohumeral Muscular Dystrophy GAITHERSBURG, Maryland and VANCOUVER, British Columbia – September 29, 2022 – miRecule, Inc., an innovator of next-generation RNA therapeutics, and SOLVE FSHD, a venture-philanthropy organization catalyzing the pace of innovation to accelerate a cure for facioscapulohumeral …

VANCOUVER, B.C., Sept 21, 2022 – SOLVE FSHD, a venture-philanthropy organization catalyzing the pace of innovation to accelerate a cure for FSHD, announced today an investment of US$3 million in Altay Therapeutics; a company focused on developing lifesaving therapies by targeting disease-causing transcription factors. This investment will support Altay Therapeutics’ unique approach to finding an …

https://fshd.ca